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Abstract
Osteosarcoma is a primary malignant tumour of the skeleton characterised by the direct formation
of immature bone or osteoid tissue by the tumour cells. The classic osteosarcoma is a rare (0.2%
of all malignant tumours) highly malignant tumour, with an estimated incidence of 3 cases/million
population/year. Osteosarcoma arises predominantly in the long bones and rarely in the soft
tissues. The age at presentation ranges from 10 to 25 years of age. Plain radiographs, computed
tomography, magnetic resonance imaging, angiography and dynamic bone scintigraphy are used for
diagnosis, evaluation the extent of tumour involvement and decision of the type of operation and,
if necessary, the type of reconstruction. Years ago, all patients with osteosarcoma were treated by
amputation but the cure rate was under 10% and almost all patients died within a year from
diagnosis. Today, for localised osteosarcoma at onset (80% of cases) treated in specialized bone
tumour centres with pre- and postoperative chemotherapy associated with surgery, the
percentage of patients cured varies between 60% and 70%. Surgery is conservative (limb salvage)
in more than 90% of patients. Prognosis is more severe (cure rate about 30%) for tumours located
in the axial skeleton and in patients with metastasis at onset.
Disease name and synonyms
Osteosarcoma
Osteogenic sarcoma
Definition and diagnostic criteria
Osteosarcoma is a primary malignant tumour of the skel-
eton characterised by the direct formation of immature
bone or osteoid tissue by the tumour cells. More rarely
osteosarcoma may arise in the soft tissue.
World Health Organization (WHO) histologic classifica-
tion of bone tumours divides osteosarcomas into central
and surface tumours, and recognises a number of sub-
types within each group [1]. This paper refers only to the
conventional central high grade primary osteosarcoma of
bone, which represents about 90% of all cases of osteosa-
rcoma.
Diagnostic criteria
To confirm diagnosis, a biopsy is always required. Biopsy
material should be obtained by the use of either a large-
core tissue biopsy or, preferably, by an open biopsy. The
use of cytologic or fine-needle aspiration should be
avoided as it frequently leads to under-diagnosis or incor-
rect diagnosis.
It is important to place the biopsy tract in an area where it
can be totally excised, if the patient will be successively
treated by limb salvage. When a malignant bone tumour
is suspected, it is preferable the initial biopsy to be done
by the surgeon who will do the definitive surgery.
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Stages of osteosarcoma
Once the diagnosis of osteosarcoma has been confirmed,
more tests should be done to detect whether cancer cells
have spread to other parts of the body.
The currently used Musculoskeletal Tumour Society stag-
ing system [2] is reported in Table 1. This system based on:
• tumour grade (I = low grade; II = high grade);
￿ tumour extension (A = intraosseous involvement only;
B = intra- and extraossseous extension);
￿ presence of distant metastases (III).
Patients with localised high grade osteosarcoma may have
stage IIA or IIB. The presence of metastatic disease, regard-
less the extent of the primary lesion, represents a stage III
disease. A bone scan should be done to rule out bone
metastases. Computed tomography scan of the chest
should also be performed to rule out pulmonary metas-
tases.
Epidemiology
Classic osteosarcoma represents approximately 15% of all
biopsy-analysed primary bone tumours. Among primary
malignant bone tumours, it ranks second in frequency
after multiple myelomas. The incidence of classic osteosa-
rcoma is 3 cases/million population/year. It represents
0.2% of all malignant tumours [3].
In about 75% of cases, patients with osteosarcoma are
between 15–25 years of age. Male are more frequently
affected than female (ration 1.5:1). Osteosarcoma rarely
occurs in patients younger than 6 years or older than 60
years. Tumours observed in older age usually develop sec-
ondary to Paget's disease, radiation or dedifferentiated
chondrosarcomas.
In general, 80% to 90% of osteosarcomas occur in the
long tubular bones. The axial skeleton is rarely affected,
more frequently in adults than in children and adoles-
cents. Femur, tibia and humerus account for about 85% of
extremity tumours, while less than 1% are found in hands
and feet bones. In the long bones, osteosarcoma usually
originate in the metaphysis. Tumours originating in the
midshaft are uncommon and these originating in the epi-
physis are very rare.
Clinical description
Most patients who present with osteogenic sarcoma of the
extremities complain of pain prior to soft tissue swelling.
This is true of any primary bone tumour, because stretch-
ing of the periosteum usually causes pain before the
tumour is discernible. Pain could also result from weaken-
ing of the bone with development of minute stress frac-
tures. Development of sudden and severe pain heralds
gross pathologic fracture, which is an uncommon finding
in adult patients. Up to 15% of paediatric patients present
a pathological fracture.
The second most common complaint is swelling, which is
related to the soft tissue mass. Although about 90% of
osteosarcoma show soft tissue extension, a few patients
complain of swelling.
Systemic symptoms as weight loss, pallor, fever, anorexia
are very uncommon.
Etiology
Etiology of osteosarcoma is unknown. A viral origin was
suggested by the evidence that bone sarcomas can be
induced in selected animals by viruses or cell-free extracts
of human osteosarcomas [4]. The only environmental
agent known to cause osteosarcoma in human is ionising
radiation [4]. Radiation is implicated in approximately
2% of osteosarcomas. An increased incidence of radio-
induced osteosarcoma is likely to be seen with a longer
survival after primary irradiation.
Several families have been described with multiple mem-
bers who developed osteosarcoma, suggesting genetic pre-
disposition to this tumour [5]. So far, the strongest genetic
predisposition is found in patients with hereditary retino-
blastoma. In patients with retinoblastoma, osteosarcoma
occurs 500 times more frequently than in the general pop-
ulation [6]. Screening large series of children with osteosa-
rcoma revealed that approximately 3% to 4% carried a
constitutional germline mutation in p53 [7]. The majority
Table 1: Surgical staging of bone sarcomas
Stage Grade Site Metastasis
IA Low Intracompartmental No
IB Low Extracompartimental No
IIA High Intracompartimental No
IIB High Extracompartimental No
III Any Any Regional or distantOrphanet Journal of Rare Diseases 2007, 2:6 http://www.OJRD.com/content/2/1/6
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of cases with germline p53 mutations represent patients
with a family history suggestive of Li-Fraumeni syndrome.
Diagnostic methods
Characteristically, plain radiographs of the involved bone
show a mixed sclerotic or lytic lesion in the affected area.
The tumour erodes through the cortex, causing elevation
of periosteum and often produces a significant soft tissue
swelling. It is important to remember that periosteal ele-
vation in an apparent bone lesion is an indication for
biopsy.
Computed tomography (CT), magnetic resonance imag-
ing (MRI), angiography and dynamic bone scintigraphy
are also important, especially to evaluate the extent of
tumour involvement. These are of great help to the sur-
geon to decide the type of operation (amputation, limb
salvage or rotationplasty) and, if necessary, the type of
reconstruction. An elevated level of serum alkaline phos-
phatase, which is found in more than 40% of patients, is
also a valuable diagnostic parameter. However, due to the
difficulties in general standardisation, this parameter may
be difficult to interpret in younger patients.
Differential diagnosis
Diagnosis of osteosarcoma is usually easy. Imaging stud-
ies alone, however, may be occasionally misleading.
Purely osteolytic osteosarcoma may mimic malignant
fibrous histiocytoma, fibrosarcoma or giant cell tumours.
Osteosarcoma with diaphyseal location may suggest
Ewing's sarcoma or lymphoma [8].
Histologically, osteosarcoma may have to be distin-
guished from a malignant fibrous histiocytoma or a
poorly differentiated fibrosarcoma. Exceptionally, an
osteosarcoma histologically mimics an osteoblastoma or
an aneurysmal bone cyst [3,8].
Management including treatment
Patients with high grade osteosarcoma are usually
grouped depending on whether the cancer is found in
only one part of the body (localised disease) or it has
spread to distant tissues or organs (generally lung):
a) Localised osteosarcoma: Cancer cells have not spread
beyond the primary bone involved, or nearby tissue in
which the cancer began.
b) Metastatic osteosarcoma: At the time of diagnosis, can-
cers cells have spread from the bone where the cancer
began to other parts of the body.
c) Recurrent osteosarcoma: The cancer reappeared in a
patient after treatment.
Specific treatment regimens are used for each group of
osteosarcoma.
Localised disease
Radical surgical treatment used alone usually fails in
about 85%–90% of patients, due to the high frequency of
micro-metastases in high grade osteosarcoma. Dramatic
therapeutic improvement achieved in the last 25 years is a
result of development of aggressive and efficient combi-
nation chemotherapy regimens to fight micro-metastases.
Rationale for this approach was that micro-metastatic dis-
ease could be more efficiently eliminated when treatment
was started early, i.e. when the total tumour burden was
still small. Thus, modern treatment programmes are typi-
cally multimodal, with surgery combined with both pre-
and postoperative chemotherapy (neoadjuvant chemo-
therapy).
As the tumour is radioresistent at standard doses, the radi-
otherapy plays no significant role in the treatment of oste-
osarcoma. It can be used, with limited effects, when
surgery is not feasible.
Drugs used in treatment of osteosarcoma are high-dose
Methotrexate (HDMTX), Cisplatin (CDP), Adriamycin
(ADM) and Ifosfamide (IF), generally used in combina-
tion. It is not clear if a 4-drugs combination (HDMTX,
CDP, ADM, IF) offers advantages over a 3-drugs combina-
tion (HDTX, CDP, DM) treatment. In some centres, ADM
and CDP are delivered intra-arterially.
Complete surgical resection is crucial for osteosarcoma
cure. It may be achieved by amputation, limb salvage
(removal of the malignant bone tumour without amputa-
tion, and replacement of bones and joints with allografts
or prosthetic devices) or rotationplasty [9]. Today, about
80%–90% of patients are treated with limb salvage, which
should be performed by an orthopaedic surgeon with a
good experience in the treatment of bone tumours. In fact,
if adequate surgical margins are not achieved, the rate of
local recurrence is very high (about 25%); in addition, the
local recurrence has a very bad prognostic significance
[10-12]. Functional results of non demolitive surgery in
these patients improved dramatically in the last ten years.
This improvement reflects the interest of the orthopaedic
oncologists in the high survival rates achieved through the
use of chemotherapy.
Metastatic disease
If CT scan of the chest shows presence of pulmonary nod-
ules, they should be resected together with the primary
tumour or at least successively, stopping all therapy. This
should be done even if, in our experience, solitary nodules
are non metastatic lesions but pseudometastasis in about
25% of cases [13]. However, in a young patient with aOrphanet Journal of Rare Diseases 2007, 2:6 http://www.OJRD.com/content/2/1/6
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classic osteogenic sarcoma the diagnosis of pseudometas-
tases should be always histologically confirmed, follow-
ing the removal of the lesion from the lung. Even if the
nodules disappear completely after preoperative chemo-
therapy, the patient should undergo a thoracotomy.
Microscopic small deposits of residual tumour may exist,
and they will most probably recur in the original CT-pos-
itive areas if the patients does not have a thoracotomy;
removal of the residual disease, which can be readily pal-
pated as a small "grain of sand" must be performed by
thoracic surgeon. The pre- and postoperative chemothera-
peutic treatment should be the same as that for patients
with localised disease. The probability of cure for the
uncommon cases in which metastatic disease at presenta-
tion is located outside the lung is less than 5% [14,15].
Recurrent osteosarcoma
Recurrence of osteosarcoma in more than 90% of patients
is located in the lung. Patients with recurrent disease,
when possible, should always be treated by surgery. Abil-
ity (and possibility) of achieving a complete resection of
metastatic lesions is the most relevant prognostic factor,
with (at first relapse) a 5-year survival rate of 20% to 45%
following complete resection of metastatic pulmonary
lesions, and 10% to 15% following complete resection of
metastases in other sites [14,15]. Factors associated with
better outcome in recurrent osteosarcoma include solitary
pulmonary nodules, a long interval from initial diagnosis
and achievement of a second complete remission. The
role of a second-line chemotherapy after treatment of
metastatic disease is not definitively established.
Prognostic factors
Combined neoadjuvant treatment gives a cure rate of
60%–70% for patients with nonmetastatic osteosarcoma
of the extremities at presentation [16-19] and of about
30% for tumours of the axial skeleton. Metastases at pres-
entation and, in localised tumours, anatomic site (extrem-
ity or axial), histological response to preoperative
chemotherapy (as measured histologically from the
resected specimen), serum levels of alkaline phosphatase
and lactate dehydrogenase are the most powerful predic-
tors of survival for patients with osteosarcoma [16-20].
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